Brief: Lb Pharmaceuticals Initiates Pivotal Phase 3 Trial (Nova-2) For Lb-102 In Patients With Schizophrenia
25/03/2026 12:31
LB Pharmaceuticals Inc LBRX.O: LB PHARMACEUTICALS INITIATES PIVOTAL PHASE 3 TRIAL (NOVA-2) FOR LB-102 IN PATIENTS WITH SCHIZOPHRENIA LB PHARMACEUTICALS INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2027 Source text: ID:nGNX9lynK7 Further company coverage: LBRX.O
Recent news on LB Pharmaceuticals
See all newsBrief: Lb Pharmaceuticals Reports Inducement Grants To New Employee Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Brief: Lb Pharmaceuticals Announces $150 Million Private Placement
LB Pharmaceuticals Q1 net loss widens on higher R&D costs